Financials data is unavailable for this security.
View more
Year on year Pharmarise Holdings Corp had net income fall from a gain of 333.00m to a loss of 351.00m despite a 4.68% increase in revenues from 52.03bn to 54.47bn. An increase in the selling, general and administrative costs as a percentage of sales from 11.62% to 12.79% was a component in the falling net income despite rising revenues.
| Gross margin | 15.04% |
|---|---|
| Net profit margin | -1.07% |
| Operating margin | -0.09% |
| Return on assets | -2.35% |
|---|---|
| Return on equity | -8.72% |
| Return on investment | -3.96% |
More ▼
Cash flow in JPYView more
In 2024, Pharmarise Holdings Corp increased its cash reserves by 49.98%, or 2.37bn. Cash Flow from Financing totalled 2.77bn or 5.09% of revenues. In addition the company generated 2.72bn in cash from operations while cash used for investing totalled 3.12bn.
| Cash flow per share | 57.59 |
|---|---|
| Price/Cash flow per share | 11.70 |
| Book value per share | 622.95 |
|---|---|
| Tangible book value per share | 70.80 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.11 |
|---|---|
| Quick ratio | 0.7392 |
| Total debt/total equity | 1.48 |
|---|---|
| Total debt/total capital | 0.5948 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -224.15%. Additionally, five year annualized dividend per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 2.05% |
|---|---|
| Div growth rate (5 year) | 0.00% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -294.43 |
More ▼
